Schroder Investment Management Group Decreases Stake in Insulet Co. (NASDAQ:PODD)

Schroder Investment Management Group lowered its position in Insulet Co. (NASDAQ:PODD - Free Report) by 100.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,775 shares of the medical instruments supplier's stock after selling 9,880,364 shares during the quarter. Schroder Investment Management Group's holdings in Insulet were worth $994,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Norges Bank bought a new stake in shares of Insulet in the 4th quarter valued at about $248,806,000. Raymond James Financial Inc. purchased a new stake in shares of Insulet in the 4th quarter valued at $69,433,000. Alecta Tjanstepension Omsesidigt acquired a new stake in Insulet during the 4th quarter worth about $53,184,000. Artisan Partners Limited Partnership grew its holdings in Insulet by 24.1% during the fourth quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier's stock worth $201,073,000 after acquiring an additional 149,524 shares during the period. Finally, Proficio Capital Partners LLC purchased a new position in shares of Insulet during the 4th quarter valued at approximately $28,422,000.

Insulet Trading Up 1.0 %

Shares of Insulet stock traded up $2.52 during mid-day trading on Friday, hitting $253.99. The stock had a trading volume of 596,739 shares, compared to its average volume of 718,834. The firm has a market cap of $17.84 billion, a P/E ratio of 43.87, a price-to-earnings-growth ratio of 3.62 and a beta of 1.30. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The firm has a 50-day moving average of $266.67 and a two-hundred day moving average of $260.38. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $289.46.

Remove Ads

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The company had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. Sell-side analysts forecast that Insulet Co. will post 3.92 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Eric Benjamin sold 12,394 shares of the business's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now directly owns 11,383 shares of the company's stock, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the sale, the director now directly owns 3,231 shares in the company, valued at approximately $888,525. This represents a 36.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. StockNews.com lowered shares of Insulet from a "buy" rating to a "hold" rating in a research note on Tuesday, March 4th. Stifel Nicolaus lifted their price target on Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a research note on Friday, February 21st. Royal Bank of Canada started coverage on Insulet in a research report on Thursday, March 6th. They set an "outperform" rating and a $340.00 price target for the company. Wells Fargo & Company raised their price objective on Insulet from $305.00 to $322.00 and gave the company an "overweight" rating in a report on Friday, February 21st. Finally, TD Cowen upped their target price on shares of Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a report on Friday, January 3rd. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $292.06.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.